Eli Lilly expects to launch the drug for OSA at the beginning ... The index is used to evaluate the severity of obstructive sleep apnea and the effectiveness of treatments for the condition. Disease ...

Key Takeaways Shares of ResMed and Inspire Medical Systems fell after the FDA approved Eli Lilly's weight-loss drug Zepbound ...

The FDA has cleared Eli Lilly’s obesity drug Zepbound as the first treatment for obstructive sleep apnea in the U.S.

The first medication for obstructive sleep apnea has been approved by the US Food and Drug Administration (FDA).

The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...

The FDA has expanded the approval of Eli Lilly’s obesity medication Zepbound to include treating moderate to severe obstructive sleep apnea for people with obesity.

The FDA has approved Lilly's Zepbound, a glp-1 agonist, for the treatment of sleep apnea, which affects 25 million Americans ...

( NewsNation) — Zepbound became the first drug approved by the Food and Drug Administration to treat obstructive sleep apnea ...

The US Food and Drug Administration has approved Zepbound (tirzepatide) as the first prescription medication for the treatment of obstructive sleep apnea (OSA).

Eli Lilly's stock has been a strong winner over the past few years, powered by its portfolio of glucagon-like peptide-1 ...

Eli Lilly's Zepbound is set to dominate the global obesity market, offering new hope with its groundbreaking treatment for ...

The federal agency authorized the use of the Eli Lilly & Co. weight loss drug for “treatment of moderate to severe ...